MedTrace Logo

Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line

NCT02187042 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2019-10-24

Study results available
· View outcomes & findings →

Summary

100 patients with metastatic and/or advanced renal cell carcinoma treated with sunitinib (Sutent) will be inclued and followed with standard care plus a call center

Principal assumption : the proportion of patients presenting with at least one grade 3 or 4 AE (whether related to sunitinib or not).

Conditions

  • Metastatic/Advanced Renal Cell Carcinoma

Interventions

OTHER

Best supportive care

BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life

OTHER

call center

Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-07
Primary Completion
2018-07-25
Completion
2018-07-25

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02187042 on ClinicalTrials.gov